IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study
This randomised, placebo-controlled trial (n=313) found all doses of sonelokimab were associated with significant benefit over placebo, with proportions achieving IGA clear or almost clear (score 0 or 1) at week 12 ranging from 48.1% to 88.2% (versus 0% placebo all p<0.0001).
Source:
The Lancet
SPS commentary:
Sonelokimab is a novel trivalent nanobody comprised of monovalent camelid-derived nanobodies specific to human interleukin (IL)-17A, IL-17F, and human serum albumin. A related commentary notes that nanobodies are a novel class of proprietary therapeutic proteins based on single-domain, camelid, heavy-chain-only antibodies. It is postulated they allow for greater stability and less complex production issues than traditional monoclonal antibodies. Nanobodies such as caplacizumab have been approved for thrombotic thrombocytopenic purpura, and other nanobodies are currently in development for various autoimmune and CNS disorders, infectious diseases, and cancers.